Stockscreener 앱 받기
32.35
2.62%
-0.87
시간 외 거래:
34.61
2.26
+6.99%
Kodiak Sciences Inc 주식(KOD)의 최신 뉴스
Results are due Monday from a study of two potential treatments for an age-related eye disease. - Stock Titan
Kodiak Sciences to report phase 3 trial results Monday By Investing.com - Investing.com Canada
Stocks to Watch: Kodiak Sciences, Circle Internet Group - Moomoo
Kodiak Sciences to report phase 3 trial results Monday - Investing.com
Kodiak Sciences Inc. (KOD) Stock Price, News, Quote & History - Yahoo! Finance Canada
Kodiak Sciences to reveal Phase 3 DAYBREAK stud... - pluang.com
Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration - Yahoo Finance
KOD Reinstated by Goldman Sachs -- Rating Set to Neutral - GuruFocus
Upcoming DAYBREAK Trial Results in Wet AMD Could Be A Game Changer For Kodiak Sciences (KOD) - Yahoo Finance
Goldman Sachs initiates Kodiak Sciences stock coverage with neutral rating - Investing.com
Goldman Sachs Reinstates Coverage on Kodiak Sciences (KOD) with Neutral Rating Amid Sector Resilience - GuruFocus
Kodiak Sciences (KOD) Stock Looks Overvalued After Its 15x Run - Yahoo Finance
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte - Zacks Investment Research
Kodiak Sciences stock faces a clinical catalyst this fall - ad-hoc-news.de
4 Biotech Stocks With Key Clinical Readouts Expected This Fall - The Globe and Mail
H.C. Wainwright reiterates Kodiak Sciences stock rating on trial outlook By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Kodiak Sciences stock rating on trial outlook - Investing.com
Kodiak Sciences: DAYBREAK Needs To Deliver More Than A Passing Grade (NASDAQ:KOD) - Seeking Alpha
3 Small-Cap Biotechs With Binary Catalysts on the Calendar - MarketBeat
KOD News | KODIAK SCIENCES INC (NASDAQ:KOD) - ChartMill
Kodiak Sciences (KOD) Races Toward Three Make-Or-Break Trial Verdicts - Yahoo Finance
Kodiak Sciences (KOD): Three Phase 3 Readouts In SightWill The Data See It Through? - RTTNews
Kodiak Sciences Inc (KOD) Peer Comparison – Compare with Others - valueresearchonline.com
What Kodiak Sciences (KOD)'s Widening Net Losses and Lower H1 Loss Per Share Mean For Shareholders - simplywall.st
Kodiak Sciences (NASDAQ:KOD) Stock Price Down 4.1%Time to Sell? - MarketBeat
Kodiak Sciences enrolls first patients in phase 3 DME trial By Investing.com - Investing.com Nigeria
HC Wainwright Lowers Earnings Estimates for Kodiak Sciences - MarketBeat
GSA Capital Partners LLP Takes $1.07 Million Position in Kodiak Sciences Inc. $KOD - MarketBeat
KOD Reiterates by HC Wainwright & Co. -- Price Target Maintained at $58 - GuruFocus
H.C. Wainwright reiterates Kodiak Sciences stock rating at buy By Investing.com - Investing.com Nigeria
HC Wainwright Reaffirms "Buy" Rating for Kodiak Sciences (NASDAQ:KOD) - MarketBeat
H.C. Wainwright reiterates Kodiak Sciences stock rating at buy - Investing.com
H.C. Wainwright Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $58 - Moomoo
Kodiak Sciences (KOD) Advances Late-Stage Trials Amid High Valua - GuruFocus
California State Teachers Retirement System Has $1.12 Million Stock Holdings in Kodiak Sciences Inc. $KOD - MarketBeat
Wall Street Zen Downgrades Kodiak Sciences (NASDAQ:KOD) to Sell - MarketBeat
UBS Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $80 - Moomoo
Kodiak Sciences (NASDAQ:KOD) Shares Gap DownTime to Sell? - MarketBeat
Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus - The Globe and Mail
Kodiak Sciences misses Q2 estimates, shares fall 5% By Investing.com - Investing.com Nigeria
Kodiak Sciences (NASDAQ:KOD) Releases Earnings Results, Misses Estimates By $0.09 EPS - MarketBeat
Kodiak Sciences misses Q2 estimates, shares fall 5% - Investing.com
Kodiak Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Kodiak Sciences Q2 net loss widens on higher R&D costs - TradingView
Kodiak Sciences posts Q2 2026 net loss of $65.6M, cash $125.9M; DAYBREAK, PEAK readouts due Sept–Dec 2026 - TradingView
BRIEF-Kodiak Sciences Q2 Net Income USD -65.643 Million - TradingView
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results - Yahoo Finance
Kodiak Sciences Enrols First Patients in Phase III ALTO Trial of KSI-501 for Diabetic Macular Edema - BioPharma APAC
Kodiak Sciences Inc. (KOD) stock price, news, quote and history - Yahoo Finance UK
3.06%
2.55%
자본화:
|
볼륨(24시간):